management of microalbuminuria in type 2 diabetes

â?? Effect of Coleus forskohlii Willd .Briqon microalbuminuria in type 2 Diabetes mellitus-An open clinical trial â??

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2016/07/007075

Enrollment

Registered

2016-07-12

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- patients with microalbuminuria in type 2 diabetes

Interventions

Intervention1: tab Coleus forskohlli: tab coleus forskohlli contains powder of Coleus forskohlliWilld.Briq after undergoing bhavna with the swarasa of same drug Control Intervention1: not applicable:

Eligibility

Inclusion criteria

Inclusion criteria: 1 Age group between 30-70 years of either sex 2 Patients on stable type 2 diabetes treatment 3 Patients who will be having positive readings for microalbuminuria for 2 readings in a gap of 90 days in type 2 Diabetes mellitus

Exclusion criteria

Exclusion criteria: 1 Type 1 diabetes 2 Increased serum urea &creatinine 3 Fatigue syndrome 4 Patients with UTI 5 Pregnant & Lactating mothers 6 Patients with other systemic disorders like IHD CKD TB AIDS 7 Patients who have a past history of MI stroke or severe Arrhythmia severe pulmonary dysfunction which interferes with the treatment will be excluded

Design outcomes

Primary

Measure	Time frame
reduced in albuminuriaTimepoint: 6 months	—

Secondary

Measure	Time frame
frequency of micturation will be reducedTimepoint: 6 months	—

Countries

India

Contacts

Public ContactDrRashmi Patil

KLEU BMK AYURVEDA MAHAVIDYALAYA

drsameernaik@rediffmail.com

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026